Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Anticancer Research

• Publication date

  2016-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.21873/ANTICANRES.11227PMID 27919951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo

  2016cited by this paper
• Survivin: a unique target for tumor therapy

  2016cited by this paper
• Faculty of 1000 evaluation for Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions.

  2016cited by this paper
• Novel Insights into the Roles of Rho Kinase in Cancer

  2016cited by this paper
• Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.

  2016cited by this paper
• Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.

  2015cited by this paper
• The Wilms' Tumor Gene WT1 − 17AA/− KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model

  2014cited by this paper
• JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.

  2014cited by this paper
• JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells

  2014cited by this paper
• Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells

  2014cited by this paper
• High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer.

  2014cited by this paper
• Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation

  2014cited by this paper
• Strategies and validation for siRNA-based therapeutics for the reversal of multi-drug resistance in cancer.

  2014cited by this paper
• Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.

  2013cited by this paper
• The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.

  2013cited by this paper
• Endothelin 1 in cancer: biological implications and therapeutic opportunities

  2013cited by this paper
• Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.

  2012cited by this paper
• Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells

  2012cited by this paper
• Targeting JNK for therapeutic depletion of stem-like glioblastoma cells

  2012cited by this paper
• HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells.

  2004cited by this paper
• Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation.

  1986cited by this paper
• Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

  1985cited by this paper

• Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies

  2025cites this paper
• LncRNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness and Chemoresistance in Pancreatic Cancer

  2025cites this paper
• A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer

  2025cites this paper
• Shear stress preconditioning enhances periodontal ligament stem cell survival.

  2025cites this paper
• RhoA-ROCK2 signaling possesses complex pathophysiological functions in cancer progression and shows promising therapeutic potential

  2024cites this paper
• Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer

  2024cites this paper
• Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy

  2023cites this paper
• CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells

  2023cites this paper
• Peristalsis-Associated Mechanotransduction Drives Malignant Progression of Colorectal Cancer

  2023cites this paper
• Role of O-GlcNAcylation on cancer stem cells: Connecting nutrient sensing to cell plasticity.

  2023cites this paper
• Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

  2022cites this paper
• Cancer Stem Cells Contribute to Drug Resistance in Multiple Different Ways.

  2022cites this paper
• GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies

  2022cites this paper
• Acquired temozolomide resistance in MGMTlow gliomas is associated with regulation of homologous recombination repair by ROCK2

  2022cites this paper
• Role of Rho GTPases in stem cell regulation.

  2021cites this paper
• The Integrative Analysis Identifies Three Cancer Subtypes and Stemness Features in Cutaneous Melanoma

  2021cites this paper
• Drug resistance and Cancer stem cells

  2021cites this paper
• Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential

  2021cites this paper
• Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches

  2021cites this paper
• Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis

  2020cites this paper
• Should we keep rocking? Portraits from targeting rho kinases in cancer.

  2020cites this paper
• Cryptosporidium: Methods and Protocols

  2020cites this paper
• Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics

  2020cites this paper
• Effect and Mechanism of Survivin on Hypoxia-Induced Multidrug Resistance of Human Laryngeal Carcinoma Cells

  2019cites this paper
• ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1

  2019cites this paper
• Identification of mechanisms of gemcitabine resistance using a whole genome shRNA screen in a novel in vitro coculture model of pancreatic cancer.

  2019cites this paper
• Targeting ROCK/LIMK/cofilin signaling pathway in cancer

  2019cites this paper
• Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response

  2018cites this paper
• AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel

  2018cites this paper
• Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling.

  2018cites this paper
• An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer

  2018cites this paper
• A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel

  2018cites this paper
• Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2

  2018cites this paper
• Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.

  2017cites this paper